Evidence map›Paper›PMID 22443238›Full record

ArticleBioconjugate chemistry2012

Evaluation of end-capped DNA modules for pRNA capture and functionalization.

Brian M Laing, Donald E Bergstrom

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Brian M LaingDepartment of Medicinal Chemistry and Molecular Pharmacology and Bindley Bioscience Center, Purdue University, West Lafayette, Indiana 47907, USA.
Donald E Bergstrom

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
Phi29 DNA-Packaging Motor for NanomedicinePN2EY018230 · NEI · UNIVERSITY OF CINCINNATI · PI GUO, PEIXUAN · 2006 to 2009
$4.6M
NCI NIH HHS P30 CA023168NCI NIH HHS P30 CA23168NEI NIH HHS PN2 EY 018230NEI NIH HHS PN2 EY018230
6 · The paper itself

Abstract

The ability of packaging RNA (pRNA) from the phi29 DNA packaging motor to form nanoassemblies and nanostructures has been exploited for the development of the nascent field of RNA nanotechnology and subsequent applications in nanomedicine. For applications in nanomedicine, it is necessary to modify the pRNA structure for the conjugation of active molecules. We have investigated end-capped double-stranded DNA segments as reversible capture reagents for pRNA. These capture agents can be designed to allow the conjugation of any desired molecule for pRNA functionalization. The results of model studies presented in this report show that 5- to 7-nucleotide overhangs on a target RNA can provide efficient handles for the high-affinity association to capped double-stranded DNA.

Indexed as

Nucleic Acid ConformationBacillus PhagesBase SequenceDNA, ViralNanostructuresNucleic Acid DenaturationNucleic Acid HybridizationOligodeoxyribonucleotidesRNATransition TemperatureDNA, ViralOligodeoxyribonucleotidesRNA

Identifiers

PMID22443238
PMCPMC3347768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.